Juvenile Idiopathic Arthritis

Canakinumab (ACZ885; Novartis) achieves major relief of symptoms in patients with systemic juvenile idiopathic arthritis (SJIA), according to encouraging results from a pivotal phase III trial with the anti-interleukin-1 beta antibody reported at the Pedi

Novartis announced recently positive results of the first pivotal Phase III trial of ACZ885 (canakinumab) in patients with systemic juvenile idiopathic arthritis (SJIA), a rare and serious childhood auto-inflammatory disease.

Bristol-Myers Squibb Company and Ono Pharmaceutical Co., Ltd., today announced an agreement to expand Bristol-Myers Squibb's territorial rights to develop and commercialize the anti-PD-1 antibody known as BMS-936558/ONO-4538, and to create a strategic all

A young Strongsville girl was diagnosed with polyarticular juvenile idiopathic arthritis (JIA) when she was just 2 years old.

ROCKVILLE, Md., Sept. 26, 2011 /PRNewswire-USNewswire/ -- Medications known as disease-modifying anti-rheumatic drugs, or DMARDs, appear to be more effective than other treatments for children with arthritis, but there is not enough evidence to support on